A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01345942
Recruitment Status : Completed
First Posted : May 2, 2011
Last Update Posted : November 2, 2016
Information provided by (Responsible Party):
Hoffmann-La Roche

April 29, 2011
May 2, 2011
November 2, 2016
May 2011
June 2011   (Final data collection date for primary outcome measure)
Effect of food on pharmacokinetics (plasma concentrations) of RO5428029 following oral administration [ Time Frame: 72 hours ]
Same as current
Complete list of historical versions of study NCT01345942 on Archive Site
Safety: Incidence of adverse events [ Time Frame: approximately 3 weeks ]
Same as current
Not Provided
Not Provided
A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers
A Randomized, Open Label, Single Dose, Two Period, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of RO5428029 Following Oral Administration in Healthy Subjects
This open label, two period, crossover study will evaluate the safety and the effect of food on the pharmacokinetics of RO5428029 in healthy volunteers. In a crossover design, healthy subjects will be randomized to receive a single oral dose of RO5428029 with or without food, with a washout period of at least 7 days between dosing and a follow-up of 7 to 10 days after last dose. Anticipated time on study will be up to 21 days.
Not Provided
Phase 1
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Healthy Volunteer
Drug: RO5428029
Single oral dose
  • Experimental: A food
    Intervention: Drug: RO5428029
  • Experimental: B without food
    Intervention: Drug: RO5428029
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
June 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers, 18 to 60 years of age inclusive
  • Body mass index (BMI) between 18 and 29.9 kg/m2, inclusive, and a minimum weight of 45 kg
  • Female subjects must be surgically sterile or post-menopausal
  • Male subjects and their partners of child-bearing potential must use 2 methods of contraception (one of which a barrier method) for the duration of the study and for at least 70 days after the last dose

Exclusion Criteria:

  • Pregnant or lactating women, and male partners of women who are pregnant or lactating
  • Women with reproductive potential
  • History (within 3 months of screening) of alcohol consumption exceeding 2 standard units per day on average; alcohol consumption will be prohibited at least 48 hours before screening
  • Positive test for drugs of abuse
  • History or symptoms of any significant disease
  • Positive for HIV, hepatitis B or hepatitis C infection
  • Participation in an investigational drug or device study within 3 months prior to screening
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP